01:58 PM EDT, 07/30/2024 (MT Newswires) -- Intellia Therapeutics ( NTLA ) said Tuesday it received the backing of UK's health regulator to conduct a clinical trial of its gene therapy NTLA-3001.

The country's Medicine and Healthcare products Regulatory Agency approved the company's phase 1/2 study to evaluate the gene editing treatment for a rare, genetic condition known as alpha-1 antitrypsin deficiency-associated lung disease.

Intellia said it will enroll up to 30 subjects in the trial. The company is also seeking approvals elsewhere as part of its development strategy for the therapy.

Intellia Therapeutics ( NTLA ) shares were down 2.4% in recent Tuesday trading.

Price: 26.30, Change: -0.64, Percent Change: -2.38